Halozyme (HALO) Therapeutics announced that it has been added to the U.S. large-cap Russell 1000 Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
- PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
- Merck granted review of Halozyme patent claims by PTAB
- Halozyme’s Strategic Positioning and Market Potential Drive Buy Rating
- Halozyme announces EC approval of Bristol Myers’ Opdivo developed with Enhanze